FIGURE 2 from A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors

Pharmacokinetic profile of PEG-Exa conjugates 3A and 3B. A, C versus t plots after intraperitoneal administration of 7.5 μmol/kg 3A and 15 μmol/kg 3B to mice (n = 4/group); data for 3A normalized to 15 μmol/kg are also shown. Average C versus t curves for each group of mice were fit to a model of absorption followed by elimination [C = C₀(exp(−k_elimt) − exp(−k_abst)] with 1/C² weighting. B, Replot of the data in A as the 3B/3B and 3A/3B ratios where slope of the latter is the rate constant for Exa release, k₁, from 3A (19).